Contrast-enhanced MR imaging

Brain and Language

Volumn 51, Issue 4, 1996, Pages 235-244

  Schima, W ^a   Mukerjee, A ^a   Saini, S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FERUMOXSIL; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERIC ACID; PERFLUORO COMPOUND; PERFLUOROOCTYL BROMIDE;

BRAIN DISEASE; BRAIN TUMOR; BREAST DISEASE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LIVER DISEASE; MAGNETIC RESONANCE ANGIOGRAPHY; MUSCULOSKELETAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; ORBIT TUMOR; PANCREAS DISEASE; PRIORITY JOURNAL; REVIEW; SPINE DISEASE; SPLEEN DISEASE; THORAX TUMOR;

EID: 22644439551     PISSN: 0093934X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0009-9260(96)80339-4     Document Type: Review

References (108)

1. Hamm B, Vogl TJ, Branding G et al. Focal liver lesions: MR imaging with Mn-DPDP-initial clinical results in 40 patients. Radiology 1992;182:167-174.
2. Hamm B, Staks T, Muehler A et al. Phase I clinical evaluation of GD-EOB-DTPA as a hepatobiliary contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995;195:785-792.
3. Vogl TJ, Pegios W, McMahon C et al. Gadobenate dimeglumine - a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. American Journal of Roentgenology 1992;158:887-892.
4. Weissleder R. Liver MR imaging with iron oxides: toward consensus and clinical practice. Radiology 1994;193:593-595.
5. Saini S, Edelman RR, Sharma P et al. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). American Journal of Roentgenology 1995;164:1147-1152.
6. Marti-Bonmati L, Vilar J Paniagua JC et al. High density barium sulphate as an oral contrast. Magnetic Resonance Imaging 1991;9:259-261.
7. Ros PR, Steinman RM, Torres GM et al. The value of barium as a gastrointestinal contrast agent in MR imaging: a comparison study in normal volunteers. American Journal of Roentgenology 1991;157:761-767.
8. Brown JJ, Duncan JR, Heiken JP et al. Perfluroctylbromide as a gastrointestinal contrast agent for MR imaging: use with and without glucagon. Radiology 1991;181:455-460.
9. ® GI as an oral magnetic resonance contrast agent. Investigative Radiology 1991;26(P):S65-66.
10. MacVicar D, Jacobsen TF, Guy R et al. Phase III trial of oral magnetic particles in MRI of abdomen and pelvis. Clinical Radiology 1993;47:183-188.
11. Laniado M, Kornmesser W, Hamm B et al. MR imaging of the gastrointestinal tract: value of Gd-DTPA. American Journal of Roentgenology 1988;150:817-821.
12. Kaminsky S, Laniado M, Gogoll M et al. Gadopentetate dimeglumine as a bowel contrast agent: safety and efficacy. Radiology 1991;178:503-508.
13. Hasso AN. Current status of enhanced magnetic resonance imaging in neuroradiology. Investigative Radiology 1993;28:S3-20.
14. Russel EJ, Schaible TF, Dillon W et al. Multicenter double blind placebo-controlled study of gadopentate dimeglumine as an MR contrast agent: evaluation in patients with cerebral lesions. American Journal of Roentgenology 1989;10:813-23.
15. Majumdar S, Zoghbi S, Gore J. Regional differences in rat brain displayed by fast MRI with superparamagnetic contrast agents. Magnetic Resonance Imaging 1988;6:611-613.
16. Warach S, Li W, Ronthal M, Edelman RR et al. Acute cerebral ischemia: Evaluation with dynamic contrast-enhanced MR imaging and MR angiography. Radiology 1992;182:41-47.
17. Runge VM, Kirsch JE, Wells JW et al. Assessment of cerebral perfusion by first-pass, dynamic, contrast-enhanced steady-state free precession MR imaging: an animal study. American Journal of Roentgenology 1993;160:593-600.
18. Rosen BR, Belliveau JW, Aronen HJ et al. Susceptibility contrast imaging of cerebral blood volume: Human experience. Magnetic Resonance in Medicine 1991;22:293-299.
19. Schörner W, Laniado M, Niendorf HP et al. Time dependent changes in image contrast in brain tumours after Gadolinium-DTPA. American Journal of Neuroradiology 1986;7:1013-1020.
20. Haustein J, Laniado M, Niendorf HP et al. Triple-dose versus standard-dose gadopentate dimeglumine: A randomised study in 199 patients. Radiology 1993;186:855-860.
21. Mehta RC, Pike GB, Haros SD et al. Central nervous system tumor, infection and infarction: Detection with gadolinium-enhanced magnetization transfer MR imaging. Radiology 1995;195:41-46.
22. Nelson K. Primary neoplasms and postoperative/postradiation changes in the brain. In: Brasch RC, ed. MRI Contrast Enhancement of the Central Nervous System New York: Raven Press, 1993:23-99.
23. Fulbright R, Sze G. Secondary neoplams and meningeal disease. In: Brasch RC, ed. MRI Contrast Enhancement of the Central Nervous System. New York: Raven Press, 1993:101-145.
24. Valk PE, Dillon WP. Diagnostic imaging of central nervous system radiation injury. In: Guten PH, Leibel SA & Sheline GE, eds. Radiation Injury to the Nervous System. New York: Raven Press, 1991:211-237.
25. Davis PC, Hudgins PA, Peterman SB et al. Diagnosis of cerebral metastases; double-dose delayed CT versus contrast-enhanced MR imaging. American Journal of Neuroradiology 1991;12:293-300.
26. Sze G, Milano E, Johnson C et al. Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. American Journal of Neuroradiology 1990;11:785-791.
27. Elster AD, Moody DM. Early cerebral infarction: gadopentetate dimeglumine enhancement. Radiology 1990;177:627-632.
28. Elster AD. MR contrast enhancement in brainstem and deep cerebral infarction. American Journal of Neuroradiology 1991;12:1127-1132.
29. Crain MR, Yuh WT, Greene GM et al. Cerebral ischemia: evaluation with contrast-enhanced MR imaging. American Journal of Neuroradiology 1991;12:631-639.
30. Fernandez RE, Rothberg M, Ferencz G et al. Lyme disease of the CNS: MR imaging findings in 14 cases. American Journal of Neuroradiology 1990;11:479-481.
31. Grossman RI, Braffman BH, Brorson JR et al. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology 1988;169:117-122.
32. Chang KH, Han MH, Roh JK et al. Gadolinium-DTPA-enhanced MR imaging of the brain in patients with meningitis: comparison with CT. American Journal of Neuroradiology 1990;11:69-76.
33. Tsuchiya K, Makita K, Furui S et al. Contrast-enhanced magnetic resonance imaging of sub- and epidural empyemas. Neuroradiology 1992;34:494-496.
34. Seltzer S, Mark AS, Atlas SW. CNS sarcoidosis: evaluation with contrast-enhanced MR imaging. American Journal of Neuroradiology 1991;12:1227-1233.
35. Sze G, Soletsky S, Bronen R, et al. MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. American Journal of Neuroradiology 1989;10: 965-975.
36. Burke JW, Podrasky AE, Bradley WG Jr. Meninges: Benign postoperative enhancement on MR images. Radiology 1990;174: 99-102.
37. Kucharczyk W, Montanera WJ. The Sella and Parasellar Region. In: Atlas SW, ed. Magnetic Resonance Imaging of the Brain and Spine. New York: Raven Press, 1991:625-668.
38. Simon JH, Szumowski S, Totterman S et al. Fat suppression MR imaging of the orbit. American Journal of Neuroradiology 1988;9:961-968.
39. Tien RD, Chu PK, Hesselink JR, Szumowski J. Intra- and paraorbital lesions: value of fat suppression MR imaging with paramagnetic contrast enhancement. American Journal of Neuroradiology 1991;12:245-253.
40. Hendrix LE, Kneeland JB, Haughton VM et al. MR imaging of optic nerve lesions: value of gadopentate dimeglumine and fat-suppression technique. American Journal of Neuroradiology 1990;11:749-754.
41. Adam G, Brab M, Bohndorf K, Günther RW. Gadolinium-DTPA-enhanced MRI of intraocular tumours. Magnetic Resonance Imaging 1990;8:683-689.
42. Barakos JA, Dillon WP, Chew WM. Orbit, skull base and pharynx: contrast-enhanced fat-suppression MR imaging. Radiology 1991;179:191-198.
43. Hudgins PA, Elster AD, Runge VM et al. Efficacy and safety of gadopentetate dimeglumine in the evaluation of the extracranial head and neck. Journal of Magnetic Resonance Imaging 1993;3:345-349.
44. Laine FJ, Braun IF, Jensen ME et al. Perineural tumour extension through the foramen ovale: evaluation with MR imaging. Radiology 1990;174:65-71.
45. Mark AS, Seltzer S, Harnsberger HR. MRI of sensorineural hearing loss: more than meets the eye? American Journal of Neuroradiology 1993;14:37-45.
46. Bergeron RT, Lo WWM, Swartz JD et al. The temporal bone. In: Som PM & Bergeron RT, eds. Head and Neck Imaging, 2nd. ed. St. Louis: Mosby Year Book, 1991:925-1115.
47. Bobman SA, Atlas SW, Listerud J et al. Postoperative lumbar spine: contrast-enhanced chemical shift MR imaging. Radiology 1991;179:557-562.
48. Ross JS, Delamarter R, Hueftle MG et al. Gadolinium-DTPA-enhanced MR imaging of the postoperative lumbar spine: time-course and mechanism of enhancement. American Journal of Roentgenology 1989;152:825-834.
49. Johnson CE, Sze G. Benign lumbar arachnoiditis: MR imaging with gadopentetate dimeglumine. American Journal of Neuroradiology 1990;110:763-770.
50. Ginsberg LE. Contrast enhancement in meningeal and extra-axial disease. Neuroimaging Clinics in North America 1994;4:133-152.
51. Sze G, Krol G, Zimmerman RD et al. Intramedullary disease of the spine: diagnosis using gadolinium-DTPA-enhanced MR imaging. American Journal of Roentgenology 1988;151:1193-2004.
52. Rahmouni A, Tempany C, Jones R et al. Lymphoma: monitoring tumor size and signal intensity with MR imaging. Radiology 1993;188:445-451.
53. Funari M, Fujita N, Peck WW et al. Cardiac tumours: assessment with Gd-DTPA enhanced MR imaging. Journal of Computer Assisted Tomography 1991;15:953-958.
54. de Roos A, van Rossum AC, van der Wall E et al. Reperfused and nonreperfused myocardial infarctions: diagnostic potential of Gd-DTPA-enhanced MR imaging. Radiology 1989;172:717-720.
55. Lauerma K, Saeed M, Wendland MF et al. The use of contrast-enhanced magnetic resonance imaging to define ischemic injury after reperfusion. Investigative Radiology 1994;29:527-535.
56. Kopans DB. The positive predictive value of mammography. American Journal of Roentgenology 1992;158:521-526.
57. Harms SE, Flamig DP. MR imaging of the breast. Journal of Magnetic Resonance Imaging 1993;3:277-283.
58. Kerslake RW, Carleton PJ, Fox JN et al. Dynamic gradient-echo and fat suppressed spin-echo contrast-enhanced MRI of the breast. Clinical Radiology 1995;50:440-454.
59. Fobben ES, Rubin CZ, Kalisher L et al. Breast MR imaging with commercially available techniques: radiologic-pathologic correlation. Radiology 1995;196:143-152.
60. Heywang-Koebrunner SH. Contrast-enhanced magnetic resonance imaging of the breast. Investigative Radiology 1994;29:94-104.
61. Heywang SH, Hilbertz T, Beck R et al. Gd-DTPA enhanced MR imaging of the breast in patients with postoperative scarring and silicon implants. Journal of Computer Assisted Tomography 1990;14:348-356.
62. Fretz CJ, Stark DD, Metz CE et al. Detection of hepatic metastases: comparsion of contrast-enhanced CT, unenhanced MR imaging, and iron oxide-enhanced MR imaging. American Journal of Roentgenology 1990;155:763-770.
63. Ros PR, Freeny PC, Harms SE et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995;196:481-488.
64. Semelka RC, Shoenut JP, Kroeker MA et al. Focal liver disease: comparison of dynamic contrast-enhanced CT and T2-weighted fat-supressed, FLASH, and dynamic gadolinium-enhanced MR imaging at 1.5 T. Radiology 1992;184:687-894.
65. Soyer P, Levesque M, Caudron C et al. MRI of liver metastases from colorectal cancer vs. CT during arterial portography. Journal of Computer Assisted Tomography 1993;17:67-74.
66. Hagspiel KD, Neidl KFW, Eichenberger AC et al. Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology 1995;196:471-478.
67. McFarland EG, Mayo-Smith WW, Saini S et al. Hepatic hemangiomas and malignant tumours: improved differentiation with heavily T2-weighted conventional spin-echo MR imaging. Radiology 1994;193:43-47.
68. Semelka RC, Brown ED, Ascher SM et al. Hepatic hemangiomas: a multi-institutional study of appearance on T2-weighted and serial gadolinium-enhanced gradient-echo MR images. Radiology 1994;192:401-406.
69. Hamm B, Fischer E, Taupitz M. Differentiation of hepatic hemangiomas from metastases by dynamic contrast-enhanced MR imaging. Journal of Computer Assisted Tomography 1990;14:205-216.
70. Mitchell DG, Saini S, Weinreb J et al. Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging. Radiology 1994;193:49-57.
71. Vogl TJ, Hammerstingl R, Pegios W et al Wertigkeit des leberspezifischen superparamagnetischen Kontrastmittels AMI-25 für die Detektion und Differentialdiagnose lebereigener Tumoren versus Metastasen. Fortschritte auf dem Gebiet der Röntgenstrahlen 1994;160:319-328.
72. Rofsky NM, Weinreb JC, Bernardino ME et al. Hepatocellular tumours: characterization with Mn-DPDP-enhanced MR imaging. Radiology 1993;188:53-59.
73. Hahn PF, Weissleder R, Stark DD et al. MR imaging of focal splenic tumours. American Journal of Roentgenology 1988;150:823-827.
74. Weissleder R, Elizondo G, Stark DD et al. The diagnosis of splenic lymphoma by MR imaging: value of superparamagnetic iron oxide. American Journal of Roentgenology 1989;152:175-180.
75. Vellet AD, Romano W, Bach DB et al. Adenocarcinoma of the pancreatic ducts: comparative evaluation with CT and MR imaging at 1.5 T. Radiology 1992;183:87-95.
76. Semelka RC, Cumming MJ, Shoenut JP et al. Islet cell tumours: comparison of dynamic contrast-enhanced CT and MR imaging with dynamic gadolinium enhancement and fat suppression. Radiology 1993;186:799-802.
77. Gehl H-B, Urhahn R, Bohndorf K et al. Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience. Radiology 1993;186:795-798.
78. Haustein J, Niendorf HP, Krestin G et al. Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure. Investigative Radiology 1992;27:153-156.
79. Semelka RC, Shoenut JP, Kroeker MA et al. Renal lesions: controlled comparison between CT and 1.5-T MR imaging with nonenhanced and gadolinium-enhanced fat-suppressed spin-echo and breath-hold FLASH techniques. Radiology 1992;182:425-430.
80. Semelka RC, Shoenut JP, Magro CM et al. Renal cancer staging: comparison of contrast-enhanced CT and gadolinium-enhanced fat-suppressed spin-echo and gradient-echo MR imaging. Journal of Magnetic Resonance Imaging 1993;3:597-602.
81. Kim SH, Choi BI, Han JK et al. Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients. Journal of Computer Assisted Tomography 1993;17:633-640.
82. Prayer L, Kainz C, Kramer J et al. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. Journal of Computer Assisted Tomography 1993;17:626-632.
83. Kim B, Semelka RC, Ascher SM et al. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 1994;193:239-245.
84. Thurnher SA. MR imaging of pelvic masses in women: contrast-enhanced vs unenhanced images. American Journal of Roentgenology 1992;159:1243-1250.
85. Hricak H, Hamm B, Semelka RC et al. Carcinoma of the uterus: use of gadopentetate dimeglumine in MR imaging. Radiology 1991;181:95-106.
86. Yamashita Y, Takahashi M, Sawada T et al. Carcinoma of the cervix: dynamic MR imaging. Radiology 1992;182:643-648.
87. Thurnher S, Hodler J, Baer S et al. Gadolinium-DOTA enhanced MR imaging of adnexal tumours. Journal of Computer Assisted Tomography 1990;14:939-949.
88. Anderson CM, Brown JJ, Balfe DM et al. MR imaging of Crohn disease: use of Perflubron as a gastrointestinal contrast agent. Journal of Magnetic Resonance Imaging 1994;4:491-496.
89. Semelka RC, Shoenut JP, Silverman R et al. Bowel disease: prospective comparison of CT and 1.5-T pre- and postcontrast MR imaging with Tl-weighted fat-suppressed and breath-hold FLASH sequences. Journal of Magnetic Resonance Imaging 1991;1:625-632.
90. Prince MR, Yucel EK, Kaufman JA et al. Dynamic gadolinium-enhanced three-dimensional abdominal MR arteriography. Journal of Magnetic Resonance Imaging 1993;3:877-881.
91. Prince MR. Gadolinium-enhanced MR aortography. Radiology 1994;191:155-164.
92. Lossef SV, Rajan SS, Patt RH et al. Gadolinium-enhanced magnitude contrast MR angiography of popliteal and tibial arteries. Radiology 1992;184:349-355.
93. Kransdorf MJ, Jelinek JS, Moser RPJ. Imaging of soft tissue tumours. Radiologic Clinics of North America 1993;31:359-372.
94. Mirowitz SA, Totty WG, Lee JKT. Characterization of musculoskeletal masses using dynamic Gd-DTPA enhanced spin-echo MRI. Journal of Computer Assisted Tomography 1992;16:120-125.
95. Benedikt RA, Jelinek JS, Kransdorf MA et al. MR imaging of soft-tissue masses: role of gadopentetate dimeglumine. Journal of Magnetic Resonance Imaging 1994;4:485-490.
96. Jones BC, Sundaram M, Kransdorf MJ. Synovial sarcoma: MR imaging findings in 34 patients. American Journal of Roentgenology 1993;161:827-830.
97. Berquist TH. Magnetic resonance imaging of primary skeletal neoplasms. Radiologic Clinics of North America 1993;31:411-424.
98. Seeger LL, Widoff BE, Bassett LW et al. Preoperative evaluation of osteosarcoma: value of gadopentetate dimeglumine-enhanced MR imaging. American Journal of Roentgenology 1991;157:347-351.
99. Schima W, Amann G, Stiglbauer R et al. Preoperative staging of osteosarcoma: efficacy of MR imaging in detecting joint involvement. American Journal of Roentgenology 1994;163: 1171-1175.
100. Fletcher BD, Hanna SL, Fairclough DL et al. Pediatric musculoskeletal tumours: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology 1992; 184:243-248.
101. Erlemann R. Dynamic, gadolinium-enhanced MR imaging to monitor response to chemotherapy (letter). Radiology 1993;186:904.
102. Vanel D, Shapeero LG, De Baere T et al. MR imaging in the follow-up of malignant and aggressive soft-tissue tumours: results of 511 examinations. Radiology 1994;190:263-268.
103. Koenig H, Sieper J, Wolf K-J. Rheumatoid arthritis; evaluation of hypervascular and fibrous pannus with dynamic MR imaging enhanced with Gd-DTPA. Radiology 1990;176:473-477.
104. Herve-Somma CMP, Sebag GH, Prieur A-M et al. Juvenile rheumatoid arthritis of the knee: MR evaluation with Gd-DOTA. Radiology 1992;182:93-98.
105. Neuhold A, Czerny C, Stiskal M. et al. Rheumatoide Arthritis des kraniozervikalen Übergangs. Radiologe 1994;34:762-769.
106. Kramer J, Recht MP, Imhof H et al. Postcontrast MR arthrography in assessment of cartilage lesions. Journal of Computer Assisted Tomography 1994;18:218-224.
107. Kramer J, Stiglbauer R, Engel A et al. MR contrast arthrography (MRA) in osteochondrosis dissecans. Journal of Computer Assisted Tomography 1992;16:254-260.
108. Chandnani VP, Yeager TD, DeBerardino T et al. Glenoid labral tears: prospective evaluation with MR imaging, MR arthrography, and CT arthrography. American Journal of Roentgenology 1993;161:1229-1235.